MX2022012898A - Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. - Google Patents

Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.

Info

Publication number
MX2022012898A
MX2022012898A MX2022012898A MX2022012898A MX2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A
Authority
MX
Mexico
Prior art keywords
solvate
hydrate
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
MX2022012898A
Other languages
English (en)
Inventor
Jacqueline Maximilien
Gopal Rajan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022012898A publication Critical patent/MX2022012898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición farmacéutica para administración oral que comprende N-(5-(4-(4-((dimetilamino)m etil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-mo rfolinofenil)acrilamida o una sal, hidrato o solvato farmacéuticamente aceptable de esta como un ingrediente activo; y una combinación de (i) un derivado de celulosa y (ii) un azúcar o poliol como diluyentes. Las composiciones descritas se caracterizan por una capacidad de fabricación mejorada, mientras se mantienen los beneficios farmacéuticos de minimizar el efecto de acuerdo con cambios en el entorno de pH en el estómago, poseen excelente estabilidad, y exhiben buena biodisponibilidad.
MX2022012898A 2020-04-14 2021-04-13 Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. MX2022012898A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US202063014277P 2020-04-23 2020-04-23
PCT/IB2021/053035 WO2021209893A1 (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Publications (1)

Publication Number Publication Date
MX2022012898A true MX2022012898A (es) 2023-01-24

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012898A MX2022012898A (es) 2020-04-14 2021-04-13 Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.

Country Status (13)

Country Link
US (2) US12138351B2 (es)
EP (1) EP4135669A1 (es)
JP (2) JP7787824B2 (es)
KR (1) KR20230002656A (es)
CN (1) CN115484937A (es)
AU (2) AU2021257662B2 (es)
CA (1) CA3180184A1 (es)
IL (1) IL297240A (es)
MX (1) MX2022012898A (es)
PH (1) PH12022552454A1 (es)
TW (1) TW202207940A (es)
UY (1) UY39171A (es)
WO (1) WO2021209893A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US20240270733A1 (en) * 2021-06-01 2024-08-15 Hangzhou Solipharma Co., Ltd. Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US6399591B1 (en) 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
WO2008057267A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2713330T3 (es) 2009-12-11 2019-05-21 Sumitomo Dainippon Pharma Co Ltd Comprimido recubierto en seco que se desintegra oralmente
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
AU2013347962B2 (en) 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
WO2015006752A1 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Combination therapies for malaria
UA120428C2 (uk) 2013-12-12 2019-12-10 Алміралл, С.А. Фармацевтичні композиції, які містять диметилфумарат
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
MX2017003181A (es) 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
TWI808938B (zh) 2016-04-07 2023-07-21 美商卡默森屈有限公司 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷
MX389966B (es) * 2017-01-20 2025-03-20 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MX393995B (es) 2017-07-28 2025-03-24 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina
DK3658553T3 (da) 2017-07-28 2022-07-25 Yuhan Corp Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf
CN111295381A (zh) 2017-07-28 2020-06-16 株式会社柳韩洋行 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法
CN110580014B (zh) * 2018-06-11 2021-03-30 北京京东尚科信息技术有限公司 用于控制自动导引运输车的方法、装置和系统
WO2020018928A1 (en) 2018-07-20 2020-01-23 Imerys Usa, Inc. Recovering sand, bentonite and organics from foundry sand waste
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
SG11202110585SA (en) 2019-04-11 2021-10-28 Goldfinch Bio Inc Spray-dried formulation of a pyridazinone trpc5 inhibitor
EP4268815A3 (en) 2019-04-17 2024-02-21 NordicCan A/S Fast disintegrating cannabinoid tablets
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CA3144840A1 (en) 2019-07-31 2021-02-04 Leonie Flurina Claude Wagner-Hattler New pharmaceutical formulation

Also Published As

Publication number Publication date
WO2021209893A1 (en) 2021-10-21
PH12022552454A1 (en) 2024-02-05
IL297240A (en) 2022-12-01
US20250177311A1 (en) 2025-06-05
CA3180184A1 (en) 2021-10-21
AU2021257662A1 (en) 2022-12-15
EP4135669A1 (en) 2023-02-22
US12138351B2 (en) 2024-11-12
JP7787824B2 (ja) 2025-12-17
AU2021257662B2 (en) 2025-06-12
CN115484937A (zh) 2022-12-16
WO2021209893A8 (en) 2022-10-13
KR20230002656A (ko) 2023-01-05
AU2025203347A1 (en) 2025-05-29
TW202207940A (zh) 2022-03-01
JP2023522634A (ja) 2023-05-31
US20210322323A1 (en) 2021-10-21
UY39171A (es) 2021-10-29
BR112022020609A2 (pt) 2022-11-29
JP2025179094A (ja) 2025-12-09

Similar Documents

Publication Publication Date Title
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
MX2022015886A (es) Derivados de amidopirimidona.
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
BR112023017624A2 (pt) Derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metila
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR121828A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato o solvato de esta
MX2024000239A (es) Medicamentos que comprenden inhibidores de la glicosidasa.
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
BR112023018766A2 (pt) Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b
CR20220644A (es) Derivados de sulfona
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
CO2025007987A2 (es) Derivados de tiadiazol como inhibidores de la sintasa de gmp-amp cíclico y usos de los mismos
EA202193266A1 (ru) Антибактериальные производные аминогликозидов
NO20073031L (no) Anvendelse av substistuerte cyklopropansyrederivater for fremstilling av medikamenter for anvendelse i behandlingen av metabolisk syndrom
UY28534A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos
ECSP055713A (es) Nuevos compuestos antimicobacterianos